Pleomorphic liposarcoma

Pleomorphic liposarcoma is a rare and aggressive malignant soft tissue tumor that arises from fat cells (adipocytes). It is the rarest subtype of liposarcoma, accounting for approximately 5% of all liposarcoma cases. This tumor is classified under soft tissue sarcomas and is characterized by the presence of pleomorphic (variably shaped) lipoblasts — abnormal fat cells with irregular, hyperchromatic nuclei and variable amounts of lipid-containing cytoplasm. Pleomorphic liposarcoma most commonly occurs in the deep soft tissues of the extremities (particularly the lower limbs), but can also arise in the retroperitoneum, trunk, and other locations. Clinically, patients typically present with a painless or sometimes painful enlarging soft tissue mass. The tumor tends to grow rapidly and can reach a considerable size before diagnosis. Due to its high-grade nature, pleomorphic liposarcoma has a significant risk of local recurrence and distant metastasis, most commonly to the lungs, liver, and bone. Constitutional symptoms such as fatigue and weight loss may occur, particularly in advanced disease. Unlike other liposarcoma subtypes, pleomorphic liposarcoma does not carry specific recurrent genetic alterations such as MDM2 amplification (seen in well-differentiated/dedifferentiated liposarcoma) or the FUS-DDIT3 fusion (seen in myxoid liposarcoma); instead, it exhibits complex karyotypes with numerous chromosomal gains and losses. The primary treatment for localized pleomorphic liposarcoma is wide surgical excision with adequate margins, often combined with radiation therapy to reduce the risk of local recurrence. Chemotherapy, typically doxorubicin-based regimens, may be considered for high-risk localized disease or metastatic cases, although response rates are variable. The overall prognosis is guarded, with five-year survival rates reported between 30% and 60%, depending on tumor size, location, depth, and resection margins. Multidisciplinary management at specialized sarcoma centers is strongly recommended for optimal outcomes.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about Pleomorphic liposarcoma